JINGXIN(SZ:002020) 智通财经网·2026-02-11 23:33Company Overview - Jingxin Pharmaceutical (002020.SZ) is an innovation-driven pharmaceutical group focusing on two core disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases. The company combines the commercialization of existing products with the continuous advancement of its product pipeline [1] - The company has shifted its strategic focus on innovative drug development towards central nervous system diseases and cardiovascular and cerebrovascular diseases, with a product portfolio that includes over 60 approved drugs, covering generic drugs, innovative drugs, traditional Chinese medicine, and biological agents [2] Financial Performance - For the fiscal years ending December 31, 2023, 2024, and the ten months ending October 31, 2025, the company reported revenues of approximately RMB 3.999 billion, RMB 4.159 billion, and RMB 3.344 billion, respectively [5] - The net profit for the same periods was approximately RMB 623 million, RMB 719 million, and RMB 629 million [4] - The gross profit margins for the fiscal years were 49.2%, 48.5%, and 48.3% respectively [6] Product Segmentation - The revenue breakdown by business line for 2023 shows that the main sources of income are from the following segments: - Pharmaceuticals: RMB 2.326 billion (58.2%) - Network: RMB 956 million (23.9%) - Medical devices: RMB 637 million (16.0%) [2] Market Overview - The Chinese pharmaceutical market is projected to grow from RMB 1,447.9 billion in 2020 to RMB 1,629.7 billion by 2024, with a compound annual growth rate (CAGR) of 3.0%. By 2035, it is expected to reach RMB 3,103.4 billion, with a CAGR of 6.5% from 2025 to 2035, surpassing the global CAGR of 5.1% during the same period [8] - The market share of patented drugs is expected to increase from 44.6% in 2020 to 70.0% by 2035, while the market share of generic drugs will decline from 55.4% to 30.0% [8] Central Nervous System Market - The global central nervous system drug market is expected to grow from USD 233.7 billion in 2020 to USD 258.8 billion by 2024, with a CAGR of 2.6%. The Chinese market is projected to grow from approximately USD 32.2 billion in 2020 to USD 34.1 billion by 2024, with a CAGR of 1.4% [10] - The insomnia drug market in China is expected to maintain a size of around USD 1.7 billion from 2020 to 2024, with a CAGR of -1.0%. However, it is projected to grow to USD 3.5 billion by 2035, with a CAGR of 7.5% from 2025 to 2035 [12] Cardiovascular Market - The global cardiovascular drug market is expected to grow from USD 115 billion in 2020 to USD 124.6 billion by 2024, with a CAGR of 2.0%. It is projected to reach USD 182 billion by 2035, with a CAGR of 3.8% from 2025 to 2035 [13] - The Chinese cardiovascular drug market is expected to decline from USD 25.5 billion in 2020 to USD 24.9 billion by 2024, with a CAGR of -0.7%. However, it is anticipated to rebound to USD 36.9 billion by 2035, with a CAGR of 4.1% from 2025 to 2035 [13]